Goodwin Procter and Wilson Sonsini Goodrich & Rosati have advised Braveheart Bio. Braveheart Bio, a clinical-stage biopharmaceutical company developing therapeutics for hypertrophic cardiomyopathy (HCM) and other...
Braveheart Bio Raises $439.9 Million in Upsized Initial Public Offering
Obsidian Therapeutics and Galera Therapeutics Announce $350 Million Merger and Private Placement
Goodwin Procter LLP has advised Obsidian Therapeutics. Sidley Austin LLP has advised Galera Therapeutics. Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. has advised the placement...
Nimbus Therapeutics’ $210 Million Private Financing
Goodwin advised Nimbus Therapeutics on the financing. Nimbus Therapeutics announced its $210 million private financing to advance its next wave of tech-enabled small molecule medicines. The...
ReNAgade Therapeutics’ $300 Million Series A Financing Round
Goodwin advised ReNAgade Therapeutics on the fundraising. ReNAgade Therapeutics announced a $300 million Series A financing round led by MPM BioImpact and F2 Ventures. ReNAgade has...
Akero Therapeutics’s $220 Million Registered Direct Offering
Goodwin advised Akero Therapeutics on the offering, and Cooley advised the underwriter involved. Akero Therapeutics (Nasdaq: AKRO) announced the closing of its underwritten registered direct offering...
ElevateBio’s $401 Million Series D Financing Round
Goodwin advised ElevateBio on the financing. ElevateBio, LLC announced the closing of its $401 million Series D financing led by the AyurMaya Capital Management Fund, managed by...
Bicara Therapeutics’ $108 Million Series B Financing
Goodwin Procter advised Bicara Therapeutics on the deal. Bicara Therapeutics announced the completion of its oversubscribed $108 million Series B financing to advance the company’s lead program...
Takeda’s Acquisition of NDI-034858 from Nimbus Therapeutics
Cleary Gottlieb represented Takeda in the transaction while Goodwin Procter advised Nimbus Therapeutics. Takeda (TSE:4502/NYSE:TAK) announced that it will acquire NDI-034858 from Nimbus Therapeutics. NDI-034858 is...
Novo Nordisk’s $1.1 Billion Acquisition of Forma Therapeutics
Davis Polk advised Novo Nordisk on the deal while Goodwin Procter represented Forma Therapeutics. Novo Nordisk announced its approximately $1.1 billion acquisition of Forma Therapeutics. Under the...
MOMA Therapeutics’ $150 Million Series B Financing
Goodwin Procter advised MOMA Therapeutics on the deal. MOMA Therapeutics announced its completion of a $150 million Series B Financing. MOMA Therapeutics is a biopharmaceutical company...
Adicet Bio’s $100.6 Million Rights Offering
Goodwin Procter advised Adicet Bio, Inc. on the deal. Adicet Bio, Inc. (Nasdaq: ACET) announced its underwritten public offering of 7,187,500 shares of its common stock, including...
Intellia Therapeutics’ $690 Million Underwritten Public Offering
Goodwin Procter advised Intellia Therapeutics on the deal. Intellia Therapeutics, Inc. (Nasdaq: NTLA) announced its $690 million underwritten public offering on the heels of releasing the first-ever...